Breast cancer prognosis varies widely among subtypes, and while outcomes have improved in recent years for estrogen receptor (ER)-expressing and HER2-overexpressing tumors, similar gains have not been achieved for patients with triple negative breast cancers lacking these molecular targets [9], most of which also belong to the poor prognosis basal-like intrinsic subtype [10, 50]. The gene discussed is ESR1; the disease is breast carcinoma.